- ￥2600
- AntibodySystem
- DQD17201
- France
- 2025年07月08日
- Research Grade Biosimilar
- Dog
- Dog
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Research Grade Anti-Dog CD152/CTLA4 Antibody (12B3)
- 抗体英文名：
Research Grade Anti-Dog CD152/CTLA4 Antibody (12B3)
- 浓度：
1 mg/ml
- 应用范围：
Research Grade Biosimilar
- 宿主：
Dog
- 适应物种：
Dog
- 保质期：
1 year
- 级别：
科研级
- 库存：
999
- 供应商：
AntibodySystem
- 克隆性：
Monoclonal
- 保存条件：
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
- 形态：
Liquid
- 亚型：
IgG2, kappa
- 规格：
100ug
| 宿主 | Dog |
| 种属反应性 | Dog |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 浓度 | 1 mg/ml |
| 纯度 | >95% as determined by SDS-PAGE. |
| 克隆类型 | Monoclonal |
| 同种型 | IgG2, kappa |
| 应用 | Research Grade Biosimilar |
| 靶标 | Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, CTLA4 |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 内毒素水平 | Please contact with the lab for this information. |
| 表达系统 | Mammalian Cells |
| Accession号 | Q9XSI1 |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 克隆号 | 12B3 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
Our products are designed for various research areas, supporting studies on 48 types of viruses, superbugs, parasites, cancer, Alzheimer's disease, Parkinson's disease, allergic responses, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验).8. Block with 4% BSA in TBST for 45 - 60 minutes. I use RIA grade BSA from USB (United States Biochemical; Catalog number 10868). I also include 0.02% NaN3 in this block and reuse it at least 5 times (Keep in 4oC between uses). We have had problems
Generation of Antibody Molecules Through Antibody Engineering
been overcome to a large extent using genetic-engineering techniques to produce chimeric mouse/human and completely human antibodies. Such an approach is particularly suitable because of the domain structure of the antibody molecule ( 2 ), where functional
both at transcriptional or posttranscriptional levels (8 -10 ). Recombinant fusion proteins consisting of various bacterial toxins selectively targeted to the tumor by virtue of single-chain anti-erbB- 2 antibody (sFv) moieties has also been utilized in this context (7 ).
技术资料暂无技术资料 索取技术资料
